Teva Pharmaceuticals’ Post

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products. Focusing on rigorous execution of our Pivot to Growth strategy throughout the year, we continued to achieve important milestones in each of its four pillars, including surpassing the outlook for our key innovative products, growing our generics business across all segments, and accelerating our early-stage innovative pipeline." - Richard Francis, Teva President and CEO We are pleased to share Teva’s Q4 and full year 2024 business results. View the full press release: https://lnkd.in/d6kC73Zt Forward-looking statements are subject to the cautionary note included in our Q4 and full year 2024 press release. #QuarterlyResults #Earnings #Tevapharm #PivotToGrowth

💡 Since 2016, over 100 #clinical trial supply chain stakeholders have worked to develop industry #standards. To ensure efficient clinical trials, stakeholders must adopt standards-based #identification for products, locations, and parties. The Global Location Number (#GLN) streamlines accurate delivery of investigational products. With proven #success in the commercial healthcare sector, it's time for the clinical trials supply chain to adopt global location identification standards. #Read this important statement from the GS1 Healthcare Clinical Trials Implementation Group, supported by Boehringer Ingelheim, Creapharm, a Myonex company, DHL, Johnson & Johnson, Pfizer, Roche and Sanofi. 🔗 Read the document here 👉 https://bit.ly/3Vz3w6e 🔗 Learn more here 👉 https://bit.ly/3Jfh4P1 #AdoptGLNsNow #GS1InClinicalTrials #GS1Healthcare #ClinicalTrials

The adoption of the Global Location Number (GLN) within the clinical trial supply chain marks a significant leap forward in ensuring the accuracy and efficiency of product deliveries. As Le Rudulier N., Head of Innovation and Group Synergy Development & IT at Creapharm stated, “It is for this reason that today we have dedicated to this standardisation and use the GS1 DataMatrix dedicated to the clinical trial products.” Collaboration among industry leaders has been crucial in driving this change as we are setting a new benchmark for how clinical trial supplies are managed globally. View the article below to learn more about the GLN initiative. #ClinicalTrials #GS1 #AdoptGLNsNow

I’m thrilled to share Teva Pharmaceuticals Q4 2024 performance, which marks the conclusion of an exceptional year filled with achievements that have strengthened our foundation and set the stage for success in 2025. As I reflect on 2024, it’s clear that the collaboration, expertise, and dedication across all our teams have been instrumental in reaching these milestones. At Teva, we are all in for better health. This commitment drives everything we do, from expanding access to high-quality medicines to developing innovative solutions that empower patients and healthcare providers. Looking ahead to this year, we are setting ambitious targets to build on the strong momentum of our 2024 results. Our teams are working together with a shared focus and determination to fuel the next phase of growth, ensuring we continue to deliver impactful results for patients and communities worldwide. Learn more about Teva's Q4 performance and our vision for the future here: https://bit.ly/3Qg2cTP Forward-looking statements are subject to the cautionary note included in our Q2 2024 press release. #WeAreAllInForBetterHealth #TevaUSA #Earnings

Collaboration is at the heart of everything we do. Ensuring that our medicines reach the people who need them most is not just a responsibility—it is a shared mission. Behind every treatment that improves a patient’s life stands a vast network of professionals whose dedication and expertise make this possible. We deeply value our partnerships with distributors, healthcare providers, and all stakeholders who contribute to making healthcare accessible and efficient. Today, we had an energizing and inspiring meeting with the exceptional team of Alliance Healthcare Romania, one of the leading pharmaceutical distributors in the country. Together, we discussed our vision and strategic projects for 2025, reinforcing our joint commitment to enhancing supply chain efficiency, ensuring continuity in patient care, and driving further innovation in pharmaceutical distribution. This partnership is a testament to how collaboration and shared goals lead to better healthcare outcomes. We are grateful for the passion, expertise, and dedication that our partners bring to the table, making a real impact in the lives of patients. As we look ahead to 2025, we are excited about the opportunities to strengthen our collaborations and continue delivering value to the healthcare ecosystem. A big thank you to the Alliance Healthcare Romania team for their continuous support, professionalism, and shared commitment to making a difference in the pharmaceutical landscape. We look forward to turning today’s discussions into impactful actions! #Collaboration #Healthcare #AllianceHealthcare #Partnerships #PharmaceuticalDistribution #2025Vision

I am excited to share Teva Pharmaceuticals financial results for Q1 2024. Thanks to the Teva team we’ve continued to deliver good results this quarter, led by the performance of our generics business across the globe and our innovative medicines growth drivers, including our treatments for tardive dyskinesia, Huntington's disease and schizophrenia. We are also advancing our biosimilar pipeline, with 16 assets in our pipeline, six of which are in Phase 3. We believe in our #PivottoGrowth strategy and we’re just getting started. There is no doubt that our direction of travel is clear and we are making great strides. Teva is deeply committed to delivering on our strategy for our people and the patients that we serve. View the full press release: https://lnkd.in/gu-by9UQ Forward-looking statements are subject to the cautionary note included in our Q1 2024 press release. #Earnings #Tevapharm #PivotToGrowth #QuarterlyResults

When we started this journey, we knew a new approach was essential to turn the rhetoric of equitable healthcare into the reality of improved access to medicines for the 2 billion people across Low and Middle-Income Countries who continue to face barriers. But what we couldn’t have imagined was how far—and how fast—we’d come this year in delivering on our mission. Thanks to an extraordinary network of supporters, partners, champions, and believers in change, we’ve made strides that were once just dreams. Your belief in our vision has turned possibility into progress, and we are endlessly grateful that you inspire us to push boundaries every single day. Yet, as proud as we are of what 2024 has delivered, we are even more energized by what lies ahead. 2025 is shaping up to be a year of even greater impact, and my fellow Axmates and I are ready to accelerate at breakneck speed to reach more lives, close more gaps, and scale what we know works. Because patients can’t wait - and neither will we. To a healthier and more equitable world. #LetsGo!

“In the second quarter of 2024, we are encouraged by the positive momentum across each of the four pillars of our Pivot to Growth strategy. Teva's global revenues of $4.2 billion increased by 7% in U.S. dollars, or 11% in local currency terms compared to the second quarter of 2023, delivering strong growth driven by our generics and innovative business" - Richard Francis, Teva President and CEO We are pleased to share Teva’s Q2 2024 business results. View the full press release: https://lnkd.in/duejCq4X Forward-looking statements are subject to the cautionary note included in our Q2 2024 press release. #QuarterlyResults #Earnings #Tevapharm #PivotToGrowth

Attending CPhI for the first time as part of the Business Development team at Jubilant Pharmova has been an exceptional and eye-opening experience. Engaging directly with customers and stakeholders provided invaluable insights into evolving market trends and the shifting dynamics of the pharmaceutical industry. The event not only deepened my understanding of global industry needs but also allowed me to cultivate meaningful relationships with key players, paving the way for future collaborations and strategic partnerships. This exposure has significantly enriched my professional journey and broadened my perspective on the complexities of the market. Truly a transformative experience that will undoubtedly shape the way I approach business development moving forward. 🚀🤝🌎 #CPhI2024 #PharmaceuticalIndustry #BusinessDevelopment #CustomerEngagement #StrategicPartnerships #MarketInsights #JubilantPharmova #NetworkingExcellence #GlobalPharma #PharmaBusiness #InnovationInPharma #PharmaNetworking #BusinessGrowth #PharmaTrends #CustomerRelations #API #CDMO #PharmaSolutions

PIE plays a vital role in your early commercialization strategy. Join Sara Rubin and Wayne Fassett in the linked webinar as they share expert tips to upscale your next PIE presentation!